Coronavirus Infection Clinical Trial
Official title:
A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study
NCT number | NCT04416919 |
Other study ID # | 11887 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 20, 2020 |
Est. completion date | January 20, 2022 |
Verified date | March 2024 |
Source | University of Oklahoma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and efficiency of an assembled modified mask in protecting health care workers against Coronavirus in case of any personal protective equipment shortage. At least 20 healthy participants will be recruited to try the modified mask. The modified masks will be made from masks that are already available as well as filters available in the pulmonary department at the Oklahoma City VA Health Care System
Status | Completed |
Enrollment | 20 |
Est. completion date | January 20, 2022 |
Est. primary completion date | June 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. All individuals older than 18 years of age, and willing to participate in the study Exclusion Criteria: 1. Individuals with known severe COPD/emphysema, Obesity Hypoventilation or hypercapnic condition 2. Individuals with allergy or reactions to latex or masks 3. Individuals reporting dyspnea or unable to breathe comfortably in these masks 4. Claustrophobic individuals 5. Inability to create a proper Seal while inhaling through a closed filter (See Below) 6. Individuals who cannot safely apply and remove these masks |
Country | Name | City | State |
---|---|---|---|
United States | Oklahoma City VA Health Care System | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
University of Oklahoma | US Department of Veterans Affairs |
United States,
Prevention CfDCa. Strategies for Optimizing the Supply of Facemasks: COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html
Qian Y, Willeke K, Grinshpun SA, Donnelly J, Coffey CC. Performance of N95 respirators: filtration efficiency for airborne microbial and inert particles. Am Ind Hyg Assoc J. 1998 Feb;59(2):128-32. doi: 10.1080/15428119891010389. — View Citation
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Success Percentage | Conduct a quantitative fit test and calculate the percentage of participants who pass the test. | 15 minutes | |
Secondary | End-tidal CO2 Variation. Description: mmHg. | Change in end-tidal CO2 from 0 to 15 minutes while wearing the Full or the Whole mask | at 0 and 15 minutes | |
Secondary | Oxygen Pulse Oximetry Variation. Description: mmHg. | Measure the change in Oxygen Pulse Oximetry from 0 to15 minutes while wearing the Full or the Whole mask | at 0 and 15 minutes. | |
Secondary | Mask Visibility. Description: Likert Scale. | Evaluate the visibility (5-point Likert scale from Absent to Complete) while wearing the Full or the Whole mask for 15 minutes | 15 minutes | |
Secondary | Willingness of usage. Description: Likert Scale. | When the mask is removed, participants will be asked about willingness to use this mask compared to N-95 masks using a 5-point Likert scale from 'Very unlikely' to 'Very likely'. | after 15 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04383899 -
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
|
||
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04532632 -
Taste and Smell Impairment in Critically Ill COVID-19 Patients
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04413435 -
Clinical Characteristics of Critically Ill Patients With COVID-19
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT04510493 -
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
|
Phase 3 | |
Active, not recruiting |
NCT04587219 -
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
|
Phase 2 | |
Withdrawn |
NCT05430958 -
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04596579 -
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04442230 -
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 |